This study examined treatment outcomes, including preserved fertility, menstrual regularity, and pregnancy outcomes, in patients with stage I epithelial ovarian cancer (EOC) or borderline ovarian tumors (BOTs) who underwent fertility-sparing surgery (FSS). Patients with stage I EOC and BOTs who were aged 18–45 years and underwent FSS between 2007 and 2022 were retrospectively reviewed. Significant differences between various subgroups in terms of disease recurrence, menstrual irregularity due to the disease, and pregnancy outcomes were analyzed. A total of 71 patients with BOTs and 33 patients with EOC were included. In the BOT group, the median age was 30 (range, 19–44) years. Recurrence occurred in eight patients, with one case exhibiting a malignant transformation into mucinous EOC. Among the 35 married patients with BOTs, 20 successfully conceived, resulting in 23 live births and 3 spontaneous abortions. A higher pregnancy rate was observed in those without prior childbirth (82.4%) than in those who had prior childbirth (33.3%). In the EOC group, the median age was 34 (range, 22–42) years. Recurrence occurred in one patient. Menstrual regularity was maintained in 69.7% of the patients. Among the 14 married patients in this group, 12 achieved a total of 15 pregnancies (including 2 twin pregnancies), 16 live births, and 1 spontaneous abortion. The results of the study confirmed that FSS is a favorable surgical option for young women with early-stage BOTs or EOC who wish to preserve their fertility. However, additional investigations are needed to validate these findings.
本研究探讨了接受保留生育功能手术(FSS)的Ⅰ期上皮性卵巢癌(EOC)或卵巢交界性肿瘤(BOTs)患者的治疗结局,包括生育力保留、月经规律性及妊娠结局。研究回顾性分析了2007年至2022年间接受FSS的18-45岁Ⅰ期EOC及BOTs患者,重点比较不同亚组在疾病复发、疾病相关月经紊乱及妊娠结局方面的差异。共纳入71例BOTs患者和33例EOC患者。BOTs组中位年龄为30岁(范围19-44岁),8例患者出现复发,其中1例恶变为黏液性EOC。在35例已婚BOTs患者中,20例成功妊娠,共获得23例活产和3例自然流产。未生育者的妊娠率(82.4%)显著高于已生育者(33.3%)。EOC组中位年龄为34岁(范围22-42岁),1例患者复发,69.7%的患者维持月经规律。该组14例已婚患者中,12例共获得15次妊娠(含2例双胎妊娠)、16例活产及1例自然流产。研究结果证实,对于有生育需求的早期BOTs或EOC年轻女性,FSS是理想的手术选择,但相关结论仍需进一步研究验证。